s186,054170,173
9.3%Operating income 81,65479,184
3.1%Interest income/(expense), net400(413)
(196.9%)Other expense, net(544)(1,389)
(60.9%)Income before taxes81,51077,382
5.3%Tax expense22,51822,973
(2.0%)NET INCOME$58,992$54,409
8.4%Net income per common shareassuming dilution
$2.32$2.0811.2%Weighted average number of sharesBasic24,93325,544Diluted25,47726,150Profit Margins:Inc/(Dec) vs
prior year profit
margin % Gross profit52.8%52.4%0.4%R&D4.7%4.1%0.6%S,G&A32.4%31.6%0.8%Operating income16.1%16.6%(0.5%)Income before taxes16.1%16.2%(0.1%)Net income11.6%11.4%0.2%Revenue Analysis for the Third Quarter and Year-To-Date FY11 and FY10Third Quarter1/1/2011
As Reported12/26/2009
As Reported% Inc/(Dec) vs
Prior YearRevenues by geographyUnited States
$79,844$74,9976.5%International
$96,945$90,1727.5%Net revenues
$176,789$165,1697.0%Disposable revenuesPlasma disposables
$59,814$59,1771.1%Blood bank disposablesPlatelet
$41,057$39,7933.2%Red cell
$11,676$12,022(2.9%)$52,732$51,8151.8%Hospital disposablesSurgical
$17,117$17,864(4.2%)OrthoPAT
$9,248$9,864(6.2%)Diagnostics
$5,220$4,33120.5%$31,584$32,059(1.5%)Subtotal
$144,130$143,0510.8%Software solutions
$16,571$8,256100.7%Equipment & other
$16,088$13,86216.1%Net revenues
$176,789$165,1697.0%Nine Months Ended1/1/2011
As Reported12/26/2009
As Reported% Inc/(Dec) vs
Prior YearRevenues by geographyUnited States
$237,893$225,2235.6%International
$268,768$251,1037.0%Net revenues
$506,661$476,3266.4%Disposable revenuesPlasma disposables
$172,245$177,469(2.9%)Blood bank disposablesPlatelet
$117,120$111,3505.2%Red cell
$34,284$
'/>"/>
SOURCE Haemonetics Corporation Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Related biology technology :1.
Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology2.
Neogen Reports 33% Increase in Net Income3.
Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans4.
New Topical Patent Research Reports Recently Published at MarketPublishers.com5.
YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT3876.
Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors7.
GeneLink Reports Third Quarter Results8.
Imagenetix, Inc. Reports Second Quarter 2011 Results9.
Transgenomic Reports Third Quarter Financial Results10.
Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results11.
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010